Two rounds, one IPO: how Singapore and Australia are funding longevity in 2025 to 2026

Longevity has no shortage of ambition. What it has lacked, in most markets, is a track record of capital actually closing rounds against it. Singapore and Australia now have one, and it is small enough to read in full.

Start with Everlab. The Melbourne based preventive health platform was founded in 2023 and by July 2025 had raised a US$10 million seed round led by Left Lane Capital. On 16 June 2026 it closed a Series A of AU$65 million led by AirTree Ventures, with Plural, Left Lane and b2venture returning alongside a notable individual backer, the cricketer Pat Cummins. The company's total raised now stands at roughly AU$80 million, and it has named the UK as its next market.

Insilico Medicine took a different route to the same conclusion, that this region will fund longevity science, but on a different balance sheet entirely. The AI drug discovery company listed on the Hong Kong Stock Exchange on 30 December 2025, raising HK$2.28 billion (about US$293 million) in the largest 2025 Hong Kong biotech listing, the first AI biotech float under HKEX's Chapter 8.05 regime. Temasek took a cornerstone position in the offering. The stock's subsequent path, a peak near HK$80.90 in February 2026 before settling closer to HK$40, is a reminder that public market longevity capital is subject to public market volatility, a different risk profile from the private rounds financing the clinics.

Then there is Morrow, a Ministry of Health licensed clinic built on a five year, venture wide capital commitment of US$156 million (roughly S$201 million), of which US$15.6 million (S$20.1 million) funds the flagship Coleman Street site that opened in 2026 after being announced in August 2025. No source names the investor or fund behind that commitment. This is patient, infrastructure grade capital, sized not to prove a growth curve in eighteen months but to fund a category defining physical asset, screening, medical and membership tiers, with a recovery wing still phasing in.

Those three events do not sit in isolation. Singapore alone has added Eternami (soft launched February 2025, opened April 2025, with Dr Dean Ho as co-founder and CTO), Asia Longevity Clinic (opened December 2025 at The Paragon), The Longevity Suite Asia's showroom (opened January 2026 at METT Singapore), The Longevity GP (launched February 2026 across two sites) and Raffles Medical Group's R17 clinic, built around the NUS developed LinAge2 biological age tool and opened in the first quarter of 2026. Australia has added the Longevity Medicine Institute in Sydney and Bespoke Longevity on the Gold Coast, founded in 2023 and 2024 respectively. None of these openings carries a disclosed funding figure in the public record, which is itself informative: most of the region's longevity clinics are opening on private or founder capital, or on funding that has not been disclosed, and Everlab, Morrow and Insilico are the exceptions that surfaced a number, not the rule.

The research layer underneath has been funded differently again, mostly through institutional and philanthropic channels rather than venture capital. The Singapore Centre for Healthy Longevity opened at Alexandra Hospital in September 2022 on a S$5 million gift from the Lien Foundation. The NUS Academy for Healthy Longevity's Clinical Trial Centre opened in October 2025, a 350 square metre facility built with industry partners Abbott, Danone, Haleon and L'Oreal. The Academy's PROMETHEUS trial was named a Milestone 1 semi finalist in the XPRIZE Healthspan competition in May 2025 and advanced to the finals in April 2026, a research validation track that runs on prize and grant capital rather than the venture capital financing the clinics and platforms above.

What eighteen months of this actually shows

The region's longevity capital formation is still early stage by count, three disclosed capital events against roughly twenty clinic, research and regulatory milestones logged over the same period, but each of the three disclosed events represents a different, credible route to scale: consumer venture capital, public equity markets with sovereign anchoring, and long duration private infrastructure capital.

Singapore's two flagship events carry different kinds of state proximity worth distinguishing rather than conflating. Temasek held a cornerstone equity position in Insilico's IPO, a direct capital relationship. Morrow, by contrast, is simply licensed under Singapore's Healthcare Services Act like every other clinic in the market, a regulatory requirement, not evidence of state linked funding, since no source names who is actually behind its US$156 million commitment. Singapore's private capital base is anchored by Temasek, EDBI, Vertex Holdings and SGInnovate, while Australia's runs through independent venture firms such as Blackbird, Square Peg and Tenmile, a fund explicitly positioned around longevity adjacent investing.

None of this proves the region has found a durable longevity investment thesis. Three events over eighteen months is a beginning, not a pattern with statistical weight. But the shape of those three events, one platform round scaling on repeat investor conviction, one science company reaching public markets with sovereign backing, one clinic anchored by a large but unattributed capital commitment, is a more coherent starting point than the raw count of clinic openings alone would suggest.